Apixaban News and Research RSS Feed - Apixaban News and Research

New guidance can help physicians determine best oral blood thinners for patients

New guidance can help physicians determine best oral blood thinners for patients

Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer. [More]
New supplement covers current knowledge and methods for management of AAICH

New supplement covers current knowledge and methods for management of AAICH

The Journal of Neurosurgery is pleased to announce today's publication of a supplement to the August issue entitled "Race Against the Clock: Overcoming Challenges in the Management of Anticoagulant-Associated Intracerebral Hemorrhage. [More]
Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. [More]
AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

An updated guideline from the American Academy of Neurology recommends that people with nonvalvular atrial fibrillation, or irregular heartbeat, take oral anticoagulants, a type of blood thinner pill, to prevent stroke. [More]
NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 – and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose. [More]
Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation. [More]

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso). [More]
Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery. [More]
Study: New genetic marker predicts warfarin dose in African-Americans

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window. [More]
New AAN guideline provides direction for use of blood thinners during surgery

New AAN guideline provides direction for use of blood thinners during surgery

A new guideline from the American Academy of Neurology will help people who take blood thinners decide whether or not to take them during surgery or other medical procedures. [More]
Rivaroxaban ruled out for extended thromboprophylaxis

Rivaroxaban ruled out for extended thromboprophylaxis

The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine. [More]
Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. [More]

Oral Eliquis receives FDA approval for treatment of clots in non-valvular atrial fibrillation patients

The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. [More]
Studies examine current treatment standards for patients with clotting disorders

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes. [More]
Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. [More]
Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban). [More]
Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California. [More]
Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). [More]

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Bristol-Myers Squibb and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that ELIQUIS (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke. [More]

Apixaban offers minor added benefit for adult patients after hip replacement

The clot-inhibiting drug apixaban was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. [More]